Prolaris was the first test to offer a direct measure of the molecular biology of an individual patient’s prostate cancer. By measuring the expression levels of genes involved in cancer cell proliferation, Prolaris is able to accurately predict disease aggressiveness.
Prolaris has been shown to be the single most clinically significant prognostic parameter of outcomes at the time of diagnosis. The test provides unique additional information combined with standard clinical factors to make the most accurate prediction of a patient’s prostate cancer aggressiveness. Prolaris has been extensively validated across multiple patient cohorts in conservative management and definitive treatment settings.
Prolaris is available as a service provided by Myriad Genetics and, pre-treatment, also as a CE-IVD kit that can be run in local molecular pathology laboratories.
This enables the pathologist to provide results within a few days. Treatment decisions can be made without unnecessary delay to maximize patient benefit.
Prolaris consistently delivers the same quality of results, regardless of the certified laboratory conducting the assay.
Prolaris, performed on FFPE biopsy samples, determines patients’ individual 10-year risk of prostate cancer specific mortality when conservatively managed, and 10-year metastasis risk after definitive therapy (surgery or radiation).
Prolaris, on FFPE resected prostate tumors (only available as a service provided by Myriad Genetics), determines biochemical recurrence risk within 10 years after prostatectomy.
With two clinically validated thresholds, the Prolaris test can identify which men are safe for Active Surveillance and those who are not. It can also identify which patients will benefit most from single-modal therapy and those who require multiple forms or greater intensity of treatment.